---
title: Study of Histological Samples From Patients With Hereditary Haemorrhagic Telangiectasia
nct_id: NCT00733655
overall_status: COMPLETED
sponsor: Imperial College London
study_type: OBSERVATIONAL
primary_condition: Telangiectasia, Hereditary Hemorrhagic
countries: United Kingdom
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00733655.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00733655"
ct_last_update_post_date: 2023-09-28
last_seen_at: "2026-05-12T07:32:38.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Study of Histological Samples From Patients With Hereditary Haemorrhagic Telangiectasia

**Official Title:** Histological Samples From Patients With Hereditary Haemorrhagic Telangiectasia

**NCT ID:** [NCT00733655](https://clinicaltrials.gov/study/NCT00733655)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 6
- **Lead Sponsor:** Imperial College London
- **Conditions:** Telangiectasia, Hereditary Hemorrhagic
- **Start Date:** 2008-09
- **Completion Date:** 2016-08
- **CT.gov Last Update:** 2023-09-28

## Brief Summary

In this study the investigators will obtain histological samples from people with hereditary haemorrhagic telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome).

## Detailed Description

HHT is an inherited condition that leads to the development of dilated and fragile blood vessels. We propose to obtain small skin samples from patients with HHT in order to analyze the samples using histological methods, and study the properties of vascular endothelial cells derived from patients. We hypothesize that these cells will show differences when compared to normal endothelial cells, which may be confirmed in single time point analyses in histological samples. We anticipate that that these findings may help to explain aspects of the HHT disease phenotype.

## Eligibility

- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients with Hereditary Haemorrhagic Telangiectasia

Exclusion Criteria:

* Unable to provide informed consent
```

## Locations (1)

- Imperial College Hammersmith Campus, London, United Kingdom

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.imperial college hammersmith campus|london||united kingdom` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00733655.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00733655*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*